Maternal and Fetal Outcomes with Metformin Therapy for Obese Pregnant Women A Randomized Control Trial | ||||
| Evidence Based Women's Health Journal | ||||
| Article 3, Volume 13, Issue 4, November 2023, Page 322-327 PDF (377.55 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ebwhj.2023.196608.1238 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Andrew Samy   1; Ahmed Abd El Aleem2; Ahmed Mohmed Abu-El Hassan3
| ||||
| 1resident doctor at obstetric and genecology ,Asyut ,Egypt | ||||
| 2lecturer of obstetric and genecology , Asyut university | ||||
| 3obstetric and gynacology , asyut university | ||||
| Abstract | ||||
| Aim of Work: To investigate the maternal and neonatal outcomes after using metformin among obese non diabetic Egyptian women. Study design: A case control, open label randomized controlled trial. Methods: A case control, open label randomized controlled trial study was conducted on 178 pregnant – 11 to 16 weeks – obese (Body mass index ≥ 30 kg/m2) non diabetic females. Our populations` cohort were equally randomized into 2 groups, cases – who were subjected to receive metformin from the date of recruitment till termination of pregnancy – and controls – who received nothing – with follow up of the maternal glucose levels and documenting the maternal and fetal outcomes. Results: Metformin appeared to have a good patient acceptability with a less weight gain during enrollment of the trial among the pregnant females with a better glycemic control. There is no difference between the 2 groups regarding incidence of developing GDM, gestational hypertension and fetal macrosomia. Conclusion: Using metformin for obese non diabetic females, from the second trimester of pregnancy can reduce the maternal weight gain during pregnancy and provide a better glycemic control with no increase in perinatal and maternal complications. | ||||
| Keywords | ||||
| Birth outcomes; fetal macrosomia; maternal weight gain; metformin | ||||
|
Statistics Article View: 149 PDF Download: 138 |
||||
